CN112955453A - 作为选择性Trk抑制剂的吡唑并嘧啶衍生物 - Google Patents

作为选择性Trk抑制剂的吡唑并嘧啶衍生物 Download PDF

Info

Publication number
CN112955453A
CN112955453A CN201980062241.XA CN201980062241A CN112955453A CN 112955453 A CN112955453 A CN 112955453A CN 201980062241 A CN201980062241 A CN 201980062241A CN 112955453 A CN112955453 A CN 112955453A
Authority
CN
China
Prior art keywords
compound
isomer
pharmaceutically acceptable
acceptable salt
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201980062241.XA
Other languages
English (en)
Other versions
CN112955453B (zh
Inventor
王建非
张杨
孙继奎
陈曙辉
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shandong Luye Pharmaceutical Co Ltd
Original Assignee
Shandong Luye Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shandong Luye Pharmaceutical Co Ltd filed Critical Shandong Luye Pharmaceutical Co Ltd
Publication of CN112955453A publication Critical patent/CN112955453A/zh
Application granted granted Critical
Publication of CN112955453B publication Critical patent/CN112955453B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Abstract

本发明公开了式(Ⅱ)所示化合物、其互变异构体或其药学上可接受的盐，并涉及其在制备治疗实体瘤相关疾病的药物的应用。

Description

PCT国内申请，说明书已公开。

Claims (23)

  1. PCT国内申请，权利要求书已公开。
CN201980062241.XA 2018-09-29 2019-09-29 作为选择性Trk抑制剂的吡唑并嘧啶衍生物 Active CN112955453B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN2018111533737 2018-09-29
CN201811153373 2018-09-29
CN2019104328215 2019-05-22
CN201910432821 2019-05-22
PCT/CN2019/109043 WO2020063965A1 (zh) 2018-09-29 2019-09-29 作为选择性Trk抑制剂的吡唑并嘧啶衍生物

Publications (2)

Publication Number Publication Date
CN112955453A true CN112955453A (zh) 2021-06-11
CN112955453B CN112955453B (zh) 2022-04-19

Family

ID=69950356

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980062241.XA Active CN112955453B (zh) 2018-09-29 2019-09-29 作为选择性Trk抑制剂的吡唑并嘧啶衍生物

Country Status (5)

Country Link
US (1) US20210403485A1 (zh)
EP (1) EP3858834A4 (zh)
JP (1) JP2022511381A (zh)
CN (1) CN112955453B (zh)
WO (1) WO2020063965A1 (zh)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114712365A (zh) * 2022-06-07 2022-07-08 山东绿叶制药有限公司 Trk抑制剂在制备治疗迟发性运动障碍药物中的应用

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115947697A (zh) * 2022-12-28 2023-04-11 苏州汉德创宏生化科技有限公司 一种3-氧代吗啉-4-羧酸叔丁酯的合成方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5342846A (en) * 1990-12-05 1994-08-30 Synphar Laboratories, Inc. 7-substituted-6-fluoro-1,4-dihydro-4-oxo-quinoline-3-carboxylic acid compounds and 7-(substituted triazolyl pyrrolidin-1-yl) 4-oxoquinoline-3-carboxylic acid derivatives useful as antibacterial agents
DK3106463T6 (da) * 2008-10-22 2020-02-24 Array Biopharma Inc Pyrazolo[1,5-]pyrimidinforbindelse som trk-kinasehæmmer
HUE035337T2 (en) * 2010-05-20 2018-05-02 Array Biopharma Inc Macrocyclic compounds as TRK kinase inhibitors
EA031863B1 (ru) * 2014-01-24 2019-03-29 ТиПи ТЕРАПЬЮТИКС, ИНК. Диарильные макроциклы в качестве модуляторов протеинкиназ
CN107735399B (zh) * 2015-07-02 2021-01-26 特普医药公司 作为蛋白质激酶的调节剂的手性二芳基大环
JOP20190092A1 (ar) * 2016-10-26 2019-04-25 Array Biopharma Inc عملية لتحضير مركبات بيرازولو[1، 5-a]بيريميدين وأملاح منها

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114712365A (zh) * 2022-06-07 2022-07-08 山东绿叶制药有限公司 Trk抑制剂在制备治疗迟发性运动障碍药物中的应用

Also Published As

Publication number Publication date
EP3858834A4 (en) 2022-06-22
CN112955453B (zh) 2022-04-19
US20210403485A1 (en) 2021-12-30
JP2022511381A (ja) 2022-01-31
WO2020063965A1 (zh) 2020-04-02
EP3858834A1 (en) 2021-08-04

Similar Documents

Publication Publication Date Title
CN111788205B (zh) 吡唑并嘧啶衍生物及其用途
CN113801114B (zh) 稠合二环杂芳基类衍生物、其制备方法及其在医药上的应用
CN115335372B (zh) 八氢吡嗪并二氮杂萘啶二酮类化生物
KR20210057767A (ko) Crbn단백질에 작용하는 삼환식 화합물
CN111372937B (zh) 噻吩并二氮杂卓衍生物及其应用
CN112654619A (zh) 三环并呋喃取代哌啶二酮类化合物
WO2021110168A1 (zh) 作为erk抑制剂的螺环类化合物及其应用
CN112955453B (zh) 作为选择性Trk抑制剂的吡唑并嘧啶衍生物
CN114728967A (zh) 作为jak抑制剂的三并杂环类化合物及其应用
CN113825755B (zh) 作为irak4抑制剂的咪唑并吡啶类化合物
CN117642407A (zh) 一种含氮杂环化合物、其制备方法、中间体及应用
CN112955454A (zh) 作为Wee1抑制剂的嘧啶并吡唑酮类衍生物及其应用
CN114761407A (zh) 作为高选择性ros1抑制剂的化合物及其应用
CN113874379A (zh) 作为Cdc7抑制剂的四并环类化合物
CN109942665B (zh) 雷公藤内酯醇衍生物及其制备方法和应用
CN112752749B (zh) 作为pd-l1免疫调节剂的氟乙烯基苯甲酰胺基化合物
CN113439080B (zh) 作为pd-l1免疫调节剂的乙烯基吡啶甲酰胺基化合物
EP3936507A1 (en) Compounds having both effects of bet bromodomain protein inhibition and pd-l1 gene regulation
WO2024056063A1 (zh) 含六氢螺环[环丙烷-1,2'-吡咯嗪]的化合物
WO2022166991A1 (zh) 吲哚啉类化合物
CN114761405A (zh) 抗hbv的1,7-萘啶类化合物
CN116891489A (zh) 苯胺取代的8-氟-吡啶[4,3-d]嘧啶类化合物

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant